{"id":"W2996164021","doi":"10.1016/j.clgc.2019.12.007","title":"Clinical Outcomes of First-line Sunitinib Followed by Immuno-oncology Checkpoint Inhibitors in Patients With Metastatic Renal Cell Carcinoma","year":2019,"lang":"en","type":"article","venue":"Clinical Genitourinary Cancer","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":false,"ca_institutions":"Alberta Health Services; CancerCare Manitoba; Health Sciences Centre; Sunnybrook Health Science Centre; Princess Margaret Cancer Centre; University of Manitoba; University of Calgary","funders":"Mailman School of Public Health, Columbia University; Foundation Medicine; Genentech; Ipsen; Bayer; Calithera Biosciences; Bristol-Myers Squibb Canada; Eisai; Eli Lilly and Company; National Comprehensive Cancer Network; F. Hoffmann-La Roche; Pfizer Canada; Alexion Pharmaceuticals; Dana-Farber Cancer Institute; Roche; Novartis; Exelixis; Sanofi; Merck; GlaxoSmithKline; Instituto de Salud Carlos III; Amgen; Pfizer; AstraZeneca; Bristol-Myers Squibb","keywords":"Medicine; Sunitinib; Hazard ratio; Discontinuation; Renal cell carcinoma; Internal medicine; Odds ratio; Oncology; Confidence interval; Retrospective cohort study; Kidney cancer","routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00104619,0.0004902597,0.002147424,0.000187253,0.00004422146,0.000008807878,0.0002765307,0.0003423278,0.000546972],"category_scores_gemma":[0.0002243576,0.0003497206,0.0007762109,0.0003583051,0.0003633848,0.0001062128,0.0002090516,0.0008584681,0.00005056922],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0004062833,"about_ca_system_score_gemma":0.0006338574,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0003380975,"about_ca_topic_score_gemma":0.0001099442,"domain_scores_codex":[0.994589,0.000525117,0.002783224,0.0008645142,0.0006345614,0.0006035371],"domain_scores_gemma":[0.9960199,0.001397877,0.0009036384,0.0009116099,0.0003384447,0.0004285046],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.006744305,0.006180661,0.9799842,0.0001954847,0.000390407,0.0002886829,0.00009146362,0.00002725355,0.00021053,6.281929e-7,0.002020385,0.00386604],"study_design_scores_gemma":[0.03074802,0.01773963,0.9442044,0.0001659966,0.0006046803,0.000007145024,0.0001147804,0.00002927014,0.002071977,0.000007024664,0.003960397,0.0003466054],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9937112,0.001148206,0.000004273816,0.0005604172,0.001038452,0.001855099,0.0001002159,0.00003172808,0.00155037],"genre_scores_gemma":[0.9960182,0.0003175027,0.0008803986,0.0004340363,0.0002356889,0.0001313288,0.000235601,0.0000694133,0.001677841],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.03577969,"threshold_uncertainty_score":0.9998955,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03917808895234826,"score_gpt":0.3492407280194261,"score_spread":0.3100626390670779,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}